Skip to main content
Erschienen in: Community Mental Health Journal 6/2014

01.08.2014 | Original Paper

Evaluation of Different Approaches for Confounding in Nonrandomised Observational Data: A Case-Study of Antipsychotics Treatment

verfasst von: E. Sarlon, A. Millier, S. Aballéa, M. Toumi

Erschienen in: Community Mental Health Journal | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Although randomised controlled trials are regarded as the gold standard for treatments efficacy, evidence from observational studies remains relevant. To address the problem of possible confounding in these studies, investigators must employ analysis methods that adjust for confounders and lead to an unbiased estimation of the treatment effect. In this paper, the authors describe two relevant statistical methods. The first method represents the classical approach consisting of a multiple regression model including the effects of treatment and covariates. This approach considers the relation between prognostic factors and the outcome variable as a relevant criterion for adjustment. The second method is based on the propensity score, and focuses on the relation between prognostic factors and treatment assignment. These approaches were applied to a cohort of 183 French schizophrenic patients who were followed for a 2-year period (from 1998 to 2000). The probability of relapse according to antipsychotic treatment exposure was modelled using Cox regression models with the two statistical methods. Goodness-of-fit criteria were used to compare the modelling approaches. This study demonstrates that the propensity score, a predicted probability, has an important balancing property that underscores its value in strengthening the results of nonrandomised observational studies.
Literatur
Zurück zum Zitat Adamina, M., et al. (2006). Propensity scores and the surgeon. British Journal of Surgery, 93(4), 389–394.PubMedCrossRef Adamina, M., et al. (2006). Propensity scores and the surgeon. British Journal of Surgery, 93(4), 389–394.PubMedCrossRef
Zurück zum Zitat Addington, D., Addington, J., & Atkinson, M. (1996). A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophrenia Research, 19(2–3), 205–212.PubMedCrossRef Addington, D., Addington, J., & Atkinson, M. (1996). A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophrenia Research, 19(2–3), 205–212.PubMedCrossRef
Zurück zum Zitat Addington, D., Addington, J., & Maticka-Tyndale, E. (1993). Assessing depression in schizophrenia: The Calgary Depression Scale. British Journal of Psychiatry. Supplement, 22, 39–44.PubMed Addington, D., Addington, J., & Maticka-Tyndale, E. (1993). Assessing depression in schizophrenia: The Calgary Depression Scale. British Journal of Psychiatry. Supplement, 22, 39–44.PubMed
Zurück zum Zitat Addington, D., Addington, J., & Maticka-Tyndale, E. (1994). Specificity of the Calgary Depression Scale for schizophrenics. Schizophrenia Research, 11(3), 239–244.PubMedCrossRef Addington, D., Addington, J., & Maticka-Tyndale, E. (1994). Specificity of the Calgary Depression Scale for schizophrenics. Schizophrenia Research, 11(3), 239–244.PubMedCrossRef
Zurück zum Zitat Addington, D., Addington, J., & Schissel, B. (1990). A depression rating scale for schizophrenics. Schizophrenia Research, 3(4), 247–251.PubMedCrossRef Addington, D., Addington, J., & Schissel, B. (1990). A depression rating scale for schizophrenics. Schizophrenia Research, 3(4), 247–251.PubMedCrossRef
Zurück zum Zitat Addington, D., et al. (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research, 6(3), 201–208.PubMedCrossRef Addington, D., et al. (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research, 6(3), 201–208.PubMedCrossRef
Zurück zum Zitat American Psychiatric Association. (1994). DSM-IV. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association. American Psychiatric Association. (1994). DSM-IV. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association.
Zurück zum Zitat Austin, P. C. (2007). The performance of different propensity score methods for estimating marginal odds ratios. Statistics in Medicine, 26(16), 3078–3094.PubMedCrossRef Austin, P. C. (2007). The performance of different propensity score methods for estimating marginal odds ratios. Statistics in Medicine, 26(16), 3078–3094.PubMedCrossRef
Zurück zum Zitat Austin, P. C. (2009). The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Medical Decision Making, 29, 661–677. Austin, P. C. (2009). The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Medical Decision Making, 29, 661–677.
Zurück zum Zitat Austin, P. C., et al. (2007). Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: A Monte Carlo study. Statistics in Medicine, 26(4), 754–768.PubMedCrossRef Austin, P. C., et al. (2007). Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: A Monte Carlo study. Statistics in Medicine, 26(4), 754–768.PubMedCrossRef
Zurück zum Zitat Barnes, T. R. (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.PubMedCrossRef Barnes, T. R. (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.PubMedCrossRef
Zurück zum Zitat Baser, O. (2006). Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health, 9(6), 377–385.PubMedCrossRef Baser, O. (2006). Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health, 9(6), 377–385.PubMedCrossRef
Zurück zum Zitat Bebbington, P. E., et al. (2005). The European Schizophrenia Cohort (EuroSC): A naturalistic prognostic and economic study. Social Psychiatry and Psychiatric Epidemiology, 40(9), 707–717.PubMedCrossRef Bebbington, P. E., et al. (2005). The European Schizophrenia Cohort (EuroSC): A naturalistic prognostic and economic study. Social Psychiatry and Psychiatric Epidemiology, 40(9), 707–717.PubMedCrossRef
Zurück zum Zitat Bender, R., & Lange, S. (2001). Adjusting for multiple testing—When and how? Journal of Clinical Epidemiology, 54(4), 343–349.PubMedCrossRef Bender, R., & Lange, S. (2001). Adjusting for multiple testing—When and how? Journal of Clinical Epidemiology, 54(4), 343–349.PubMedCrossRef
Zurück zum Zitat Bora, E., Yucel, M., & Pantelis, C. (2009). Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: Meta-analytic study. British Journal of Psychiatry, 195(6), 475–482.PubMedCrossRef Bora, E., Yucel, M., & Pantelis, C. (2009). Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: Meta-analytic study. British Journal of Psychiatry, 195(6), 475–482.PubMedCrossRef
Zurück zum Zitat Cascio, M. T., et al. (2012). Gender and duration of untreated psychosis: A systematic review and meta-analysis. Early Intervention in Psychiatry, 6(2), 115–127.PubMedCrossRef Cascio, M. T., et al. (2012). Gender and duration of untreated psychosis: A systematic review and meta-analysis. Early Intervention in Psychiatry, 6(2), 115–127.PubMedCrossRef
Zurück zum Zitat Cepeda, M. S., et al. (2003). Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. American Journal of Epidemiology, 158(3), 280–287.PubMedCrossRef Cepeda, M. S., et al. (2003). Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. American Journal of Epidemiology, 158(3), 280–287.PubMedCrossRef
Zurück zum Zitat Cleophas, T. J., & Zwinderman, A. H. (2007). Clinical trials: How to assess confounding and why so. Current Clinical Pharmacology, 2(2), 129–133.PubMedCrossRef Cleophas, T. J., & Zwinderman, A. H. (2007). Clinical trials: How to assess confounding and why so. Current Clinical Pharmacology, 2(2), 129–133.PubMedCrossRef
Zurück zum Zitat CNIL. (2004). Act no 78-17 of 6 January 1978 on data processing, data files and individual liberties (amended by the Act of 6 August 2004 relating to the protection of individuals with regard to the processing of personal data), J.o.d.l.R.F.A.N.e. Sénat, Editor, France. CNIL. (2004). Act no 78-17 of 6 January 1978 on data processing, data files and individual liberties (amended by the Act of 6 August 2004 relating to the protection of individuals with regard to the processing of personal data), J.o.d.l.R.F.A.N.e. Sénat, Editor, France.
Zurück zum Zitat Cook, E. F., & Goldman, L. (1989). Performance of tests of significance based on stratification by a multivariate confounder score or by a propensity score. Journal of Clinical Epidemiology, 42(4), 317–324.PubMedCrossRef Cook, E. F., & Goldman, L. (1989). Performance of tests of significance based on stratification by a multivariate confounder score or by a propensity score. Journal of Clinical Epidemiology, 42(4), 317–324.PubMedCrossRef
Zurück zum Zitat Correll, C. U., & Gallego, J. A. (2012). Antipsychotic polypharmacy: A comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatric Clinics of North America, 35(3), 661–681.PubMedCentralPubMedCrossRef Correll, C. U., & Gallego, J. A. (2012). Antipsychotic polypharmacy: A comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatric Clinics of North America, 35(3), 661–681.PubMedCentralPubMedCrossRef
Zurück zum Zitat Correll, C. U., et al. (2007). Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia Research, 89(1–3), 91–100.PubMedCentralPubMedCrossRef Correll, C. U., et al. (2007). Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia Research, 89(1–3), 91–100.PubMedCentralPubMedCrossRef
Zurück zum Zitat Correll, C. U., et al. (2009). Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophrenia Bulletin, 35(2), 443–457.PubMedCentralPubMedCrossRef Correll, C. U., et al. (2009). Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophrenia Bulletin, 35(2), 443–457.PubMedCentralPubMedCrossRef
Zurück zum Zitat D’Agostino, R. B., Jr. (1998). Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics in Medicine, 17(19), 2265–2281.PubMedCrossRef D’Agostino, R. B., Jr. (1998). Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics in Medicine, 17(19), 2265–2281.PubMedCrossRef
Zurück zum Zitat Dausch, B. M., Miklowitz, D. J., & Richards, J. A. (1996). Global assessment of relational functioning scale (GARF): II. Reliability and validity in a sample of families of bipolar patients. Family Process, 35(2), 175–189.PubMedCrossRef Dausch, B. M., Miklowitz, D. J., & Richards, J. A. (1996). Global assessment of relational functioning scale (GARF): II. Reliability and validity in a sample of families of bipolar patients. Family Process, 35(2), 175–189.PubMedCrossRef
Zurück zum Zitat de Leon, J. (2008). Beyond the “hype” on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use. Journal of Clinical Psychopharmacology, 28(2), 125–131.PubMedCrossRef de Leon, J. (2008). Beyond the “hype” on the association between metabolic syndrome and atypical antipsychotics: The confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use. Journal of Clinical Psychopharmacology, 28(2), 125–131.PubMedCrossRef
Zurück zum Zitat Doan, B. Q., et al. (2006). Covariate-based linkage analysis: Application of a propensity score as the single covariate consistently improves power to detect linkage. European Journal of Human Genetics, 14(9), 1018–1026.PubMedCrossRef Doan, B. Q., et al. (2006). Covariate-based linkage analysis: Application of a propensity score as the single covariate consistently improves power to detect linkage. European Journal of Human Genetics, 14(9), 1018–1026.PubMedCrossRef
Zurück zum Zitat Gail, M., Wieand, S., & Piantadosi, S. (1984). Biased estimates of treatment effect in randomized experiment with nonlinear regressions and omitted covariates. Biometrika, 7, 431–444.CrossRef Gail, M., Wieand, S., & Piantadosi, S. (1984). Biased estimates of treatment effect in randomized experiment with nonlinear regressions and omitted covariates. Biometrika, 7, 431–444.CrossRef
Zurück zum Zitat Gilmer, T. P., et al. (2007). Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999–2004. Psychiatric Services (Washington, D. C.), 58(7), 1007–1010.CrossRef Gilmer, T. P., et al. (2007). Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999–2004. Psychiatric Services (Washington, D. C.), 58(7), 1007–1010.CrossRef
Zurück zum Zitat Goghari, V. M., et al. (2012) A 20-year multi-follow-up of hallucinations in schizophrenia, other psychotic, and mood disorders. Psychological Medicine, 43(6), 1151–1160. Goghari, V. M., et al. (2012) A 20-year multi-follow-up of hallucinations in schizophrenia, other psychotic, and mood disorders. Psychological Medicine, 43(6), 1151–1160.
Zurück zum Zitat Goldman, H. H., Skodol, A. E., & Lave, T. R. (1992). Revising axis V for DSM-IV: A review of measures of social functioning. American Journal of Psychiatry, 149(9), 1148–1156.PubMed Goldman, H. H., Skodol, A. E., & Lave, T. R. (1992). Revising axis V for DSM-IV: A review of measures of social functioning. American Journal of Psychiatry, 149(9), 1148–1156.PubMed
Zurück zum Zitat Groenwold, R. H., et al. (2011). Selection of confounding variables should not be based on observed associations with exposure. European Journal of Epidemiology, 26, 589–593.PubMedCentralPubMedCrossRef Groenwold, R. H., et al. (2011). Selection of confounding variables should not be based on observed associations with exposure. European Journal of Epidemiology, 26, 589–593.PubMedCentralPubMedCrossRef
Zurück zum Zitat Hanley, J. A., & McNeil, B. J. (1982). The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 143(1), 29–36.PubMedCrossRef Hanley, J. A., & McNeil, B. J. (1982). The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 143(1), 29–36.PubMedCrossRef
Zurück zum Zitat Joukamaa, M., et al. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188, 122–127.PubMedCrossRef Joukamaa, M., et al. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188, 122–127.PubMedCrossRef
Zurück zum Zitat Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276.PubMedCrossRef Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276.PubMedCrossRef
Zurück zum Zitat Kay, S. R., Opler, L. A., & Lindenmayer, J. P. (1989). The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation. British Journal of Psychiatry. Supplement, 7, 59–67.PubMed Kay, S. R., Opler, L. A., & Lindenmayer, J. P. (1989). The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation. British Journal of Psychiatry. Supplement, 7, 59–67.PubMed
Zurück zum Zitat Khan, A. (2010). Antipsychotic polypharmacy is not associated with increased mortality from natural causes in patients with schizophrenia compared to monotherapy. Evidence Based Mental Health, 13(3), 90. Khan, A. (2010). Antipsychotic polypharmacy is not associated with increased mortality from natural causes in patients with schizophrenia compared to monotherapy. Evidence Based Mental Health, 13(3), 90.
Zurück zum Zitat Kirkbride, J. B., et al. (2012). Incidence of schizophrenia and other psychoses in England, 1950–2009: A systematic review and meta-analyses. PLoS ONE, 7(3), e31660.PubMedCentralPubMedCrossRef Kirkbride, J. B., et al. (2012). Incidence of schizophrenia and other psychoses in England, 1950–2009: A systematic review and meta-analyses. PLoS ONE, 7(3), e31660.PubMedCentralPubMedCrossRef
Zurück zum Zitat Klungel, O. H., et al. (2004). Methods to assess intended effects of drug treatment in observational studies are reviewed. Journal of Clinical Epidemiology, 57(12), 1223–1231.PubMedCrossRef Klungel, O. H., et al. (2004). Methods to assess intended effects of drug treatment in observational studies are reviewed. Journal of Clinical Epidemiology, 57(12), 1223–1231.PubMedCrossRef
Zurück zum Zitat Kovess, V., et al. (1995). Has the sectorization of psychiatric services in France really been effective? Social Psychiatry and Psychiatric Epidemiology, 30(3), 132–138.PubMedCrossRef Kovess, V., et al. (1995). Has the sectorization of psychiatric services in France really been effective? Social Psychiatry and Psychiatric Epidemiology, 30(3), 132–138.PubMedCrossRef
Zurück zum Zitat Kreyenbuhl, J., et al. (2007). Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatric Services (Washington, D. C.), 58(7), 983–990.CrossRef Kreyenbuhl, J., et al. (2007). Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatric Services (Washington, D. C.), 58(7), 983–990.CrossRef
Zurück zum Zitat Kwiatkowski, F., et al. (2007). Propensity score: Interest and limits. Bulletin du Cancer, 94(7), 680–686.PubMed Kwiatkowski, F., et al. (2007). Propensity score: Interest and limits. Bulletin du Cancer, 94(7), 680–686.PubMed
Zurück zum Zitat Lader, M. (1995). What is relapse in schizophrenia? International Clinical Psychopharmacology, 9(Suppl 5), 5–9.PubMed Lader, M. (1995). What is relapse in schizophrenia? International Clinical Psychopharmacology, 9(Suppl 5), 5–9.PubMed
Zurück zum Zitat Lehman, A. F., et al. (2004a). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry, 161(2 Suppl), 1–56.PubMed Lehman, A. F., et al. (2004a). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry, 161(2 Suppl), 1–56.PubMed
Zurück zum Zitat Lehman, A. F., et al. (2004b). The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. Schizophrenia Bulletin, 30(2), 193–217.PubMedCrossRef Lehman, A. F., et al. (2004b). The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. Schizophrenia Bulletin, 30(2), 193–217.PubMedCrossRef
Zurück zum Zitat Martens, E. P., et al. (2008). Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods. Pharmacoepidemiology and Drug Safety, 17(1), 1–8.PubMedCrossRef Martens, E. P., et al. (2008). Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods. Pharmacoepidemiology and Drug Safety, 17(1), 1–8.PubMedCrossRef
Zurück zum Zitat Misawa, F., et al. (2011). Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects? A cross-sectional study. BMC Psychiatry, 11, 118.PubMedCentralPubMedCrossRef Misawa, F., et al. (2011). Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects? A cross-sectional study. BMC Psychiatry, 11, 118.PubMedCentralPubMedCrossRef
Zurück zum Zitat Montout, C., et al. (2002). Neuroleptics and mortality in schizophrenia: Prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophrenia Research, 57(2–3), 147–156.PubMedCrossRef Montout, C., et al. (2002). Neuroleptics and mortality in schizophrenia: Prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophrenia Research, 57(2–3), 147–156.PubMedCrossRef
Zurück zum Zitat Moore, T. A., et al. (2007). The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. Journal of Clinical Psychiatry, 68(11), 1751–1762.PubMedCrossRef Moore, T. A., et al. (2007). The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. Journal of Clinical Psychiatry, 68(11), 1751–1762.PubMedCrossRef
Zurück zum Zitat Morgan, M. G., et al. (2003). Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: A 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. Psychiatry Research, 117(2), 127–135.PubMedCrossRef Morgan, M. G., et al. (2003). Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: A 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. Psychiatry Research, 117(2), 127–135.PubMedCrossRef
Zurück zum Zitat NICE. (2002). Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. London: National Institute for Clinical Excellence. NICE. (2002). Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. London: National Institute for Clinical Excellence.
Zurück zum Zitat Riou Franca, L., et al. (2006). Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. International Journal of Technology Assessment in Health Care, 22(1), 101–108.PubMed Riou Franca, L., et al. (2006). Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. International Journal of Technology Assessment in Health Care, 22(1), 101–108.PubMed
Zurück zum Zitat Rosembaum, P., & Rubin, D. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70, 41–45.CrossRef Rosembaum, P., & Rubin, D. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70, 41–45.CrossRef
Zurück zum Zitat Rubin, D. B. (1997). Estimating causal effects from large data sets using propensity scores. Annals of Internal Medicine, 127(8 Pt 2), 757–763.PubMedCrossRef Rubin, D. B. (1997). Estimating causal effects from large data sets using propensity scores. Annals of Internal Medicine, 127(8 Pt 2), 757–763.PubMedCrossRef
Zurück zum Zitat Schisterman, E. F., Cole, S. R., & Platt, R. W. (2009). Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology, 20(4), 488–495.PubMedCentralPubMedCrossRef Schisterman, E. F., Cole, S. R., & Platt, R. W. (2009). Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology, 20(4), 488–495.PubMedCentralPubMedCrossRef
Zurück zum Zitat Schneeweiss, S., & Avorn, J. (2009). Antipsychotic agents and sudden cardiac death—How should we manage the risk? New England Journal of Medicine, 360(3), 294–296.PubMedCrossRef Schneeweiss, S., & Avorn, J. (2009). Antipsychotic agents and sudden cardiac death—How should we manage the risk? New England Journal of Medicine, 360(3), 294–296.PubMedCrossRef
Zurück zum Zitat Sebastian, C. S., Glazer, W., & Buckley, P. F. (2004). Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. Current Medicinal Chemistry, 11(3), 329–342.PubMedCrossRef Sebastian, C. S., Glazer, W., & Buckley, P. F. (2004). Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. Current Medicinal Chemistry, 11(3), 329–342.PubMedCrossRef
Zurück zum Zitat Shah, B. R., et al. (2005). Propensity score methods gave similar results to traditional regression modeling in observational studies: A systematic review. Journal of Clinical Epidemiology, 58(6), 550–559.PubMedCrossRef Shah, B. R., et al. (2005). Propensity score methods gave similar results to traditional regression modeling in observational studies: A systematic review. Journal of Clinical Epidemiology, 58(6), 550–559.PubMedCrossRef
Zurück zum Zitat Stukel, T. A., et al. (2007). Analysis of observational studies in the presence of treatment selection bias: Effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA, 297(3), 278–285.PubMedCentralPubMedCrossRef Stukel, T. A., et al. (2007). Analysis of observational studies in the presence of treatment selection bias: Effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA, 297(3), 278–285.PubMedCentralPubMedCrossRef
Zurück zum Zitat Sturmer, T., et al. (2005). Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: Nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. American Journal of Epidemiology, 161(9), 891–898.PubMedCentralPubMedCrossRef Sturmer, T., et al. (2005). Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: Nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. American Journal of Epidemiology, 161(9), 891–898.PubMedCentralPubMedCrossRef
Zurück zum Zitat Sturmer, T., et al. (2006). A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. Journal of Clinical Epidemiology, 59(5), 437–447.PubMedCentralPubMedCrossRef Sturmer, T., et al. (2006). A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. Journal of Clinical Epidemiology, 59(5), 437–447.PubMedCentralPubMedCrossRef
Zurück zum Zitat Tiihonen, J., et al. (2012). Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Archives of General Psychiatry, 69(5), 476–483.PubMedCrossRef Tiihonen, J., et al. (2012). Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Archives of General Psychiatry, 69(5), 476–483.PubMedCrossRef
Zurück zum Zitat VanderWeele, T. J. (2009). On the relative nature of overadjustment and unnecessary adjustment. Epidemiology, 20(4), 496–499.PubMedCrossRef VanderWeele, T. J. (2009). On the relative nature of overadjustment and unnecessary adjustment. Epidemiology, 20(4), 496–499.PubMedCrossRef
Zurück zum Zitat Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998). Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry, 173, 325–329.PubMedCrossRef Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998). Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry, 173, 325–329.PubMedCrossRef
Zurück zum Zitat Weiden, P., et al. (1994). Rating of medication influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin, 20(2), 297–310.PubMedCrossRef Weiden, P., et al. (1994). Rating of medication influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin, 20(2), 297–310.PubMedCrossRef
Zurück zum Zitat Weinmann, S., Read, J., & Aderhold, V. (2009). Influence of antipsychotics on mortality in schizophrenia: Systematic review. Schizophrenia Research, 113(1), 1–11.PubMedCrossRef Weinmann, S., Read, J., & Aderhold, V. (2009). Influence of antipsychotics on mortality in schizophrenia: Systematic review. Schizophrenia Research, 113(1), 1–11.PubMedCrossRef
Zurück zum Zitat Weitzen, S., et al. (2005). Weaknesses of goodness-of-fit tests for evaluating propensity score models: The case of the omitted confounder. Pharmacoepidemiology and Drug Safety, 14(4), 227–238.PubMedCrossRef Weitzen, S., et al. (2005). Weaknesses of goodness-of-fit tests for evaluating propensity score models: The case of the omitted confounder. Pharmacoepidemiology and Drug Safety, 14(4), 227–238.PubMedCrossRef
Zurück zum Zitat WMA. (2008). Declaration of Helsinki, ethical principles for medical research involving human subjects. G.A. World Medical Association, Editor. Seoul. WMA. (2008). Declaration of Helsinki, ethical principles for medical research involving human subjects. G.A. World Medical Association, Editor. Seoul.
Metadaten
Titel
Evaluation of Different Approaches for Confounding in Nonrandomised Observational Data: A Case-Study of Antipsychotics Treatment
verfasst von
E. Sarlon
A. Millier
S. Aballéa
M. Toumi
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Community Mental Health Journal / Ausgabe 6/2014
Print ISSN: 0010-3853
Elektronische ISSN: 1573-2789
DOI
https://doi.org/10.1007/s10597-014-9723-x

Weitere Artikel der Ausgabe 6/2014

Community Mental Health Journal 6/2014 Zur Ausgabe

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.